NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Eisai Appoints Regulatory VP
Eisai, the U.S. pharmaceutical subsidiary of Eisai Co., has appointed Maria Garrigan, as VP, global regulatory strategy for the oncology business group (OBG). In this role, Ms. Garrigan is responsible for leading the oncology regulatory affairs teams in the United States and United Kingdom. Ms. Garrigan, who joins Eisai with more than 20 years of global regulatory experience, works closely with the company’s commercial and OBG strategy organization on the development, planning and management of global regulatory strategies and activities for Eisai’s oncology projects.
She joins Eisai from Bayer HealthCare Pharmaceuticals, where she served as senior director, global regulatory affairs, specialty medicine, oncology, since 2013. Her regulatory affairs career began at Berlex, which was acquired by Bayer in 2006.
The Medicines Company
The Medicines Company has appointed Tony Kingsley as president and chief operating officer. Mr. Kingsley helps oversee the day-to-day operations of the company and will lead the company’s commercial activities.
Before joining The Medicines Company, Mr. Kingsley was executive VP, global commercial operations at Biogen, where he oversaw the launch of multiple new therapies, including Tecfidera.
Dr. Aarti Shah
Lilly Names Chief
Eli Lilly and Company has promoted Aarti Shah, Ph.D., to senior VP and chief information officer. She has been the global brand development leader for immunology since 2013.
Dr. Shah joined Lilly in 1994 as a senior statistician after completing her doctorate in applied statistics from the University of California, Riverside. During her career at Lilly, she has held many technical and administrative leadership positions, both in the United States and abroad, including serving as VP for biometrics and advanced analytics and as executive director of global information sciences.
In her new role, she leads the efforts of a worldwide IT organization with more than 1,300 employees, in addition to many contractors and external business partners, to deliver innovative IT solutions to the business.
Bicycle Therapeutics Establishes U.S. Operations and Appoints President
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides platform, has established U.S. operations with headquarters in Cambridge, Mass., and named Rosamond Deegan, as president and chief business officer.
In this newly created role, Ms. Deegan is responsible for leading Bicycle Therapeutics’ business development activities and is establishing a U.S. team aligned with the company’s focus on oncology clinical development.
Ms. Deegan joined Bicycle Therapeutics from Trevena, where she most recently served on the senior leadership team as senior VP, business development and operations.
Dr. Michael Fischbach
Revolution Medicines’ Co-founder joins Company
Revolution Medicines, a company focused on the discovery and development of innovative drugs inspired by natural products, has announced that chemical biologist Michael Fischbach, Ph.D., has joined the company as an academic co-founder.
Dr. Fischbach is an associate professor in the department of bioengineering and therapeutic sciences at University of California, San Francisco and a member of the California Institute for Quantitative Biosciences. He is the recipient of numerous awards and grants, and he and his research laboratory are recognized widely for their combined use of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome.
Dr. Ji Li
BeiGene Appoints Global Head of Business Development
BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has appointed Ji Li, Ph.D., as executive VP, global head of business development.
Before joining BeiGene, Dr. Li served as VP of business development and licensing at Merck Research Laboratories, a subsidiary of Merck & Co., where he was responsible for business development activities of late-stage inbound and outbound opportunities. In addition, he led the team in executing external clinical collaborations in the immune-oncology space and Merck’s R&D business development efforts in Japan and China.
Dr. Sandy Macrae
Sangamo BioSciences announces Leadership Transition
Sangamo BioSciences, a leader in therapeutic genome editing, has appointed Alexander ‘Sandy’ Macrae, M.B. Ch.B, Ph.D., as president and CEO.
Dr. Macrae, a physician scientist with deep experience in clinical development and global business strategy, most recently served as global medical officer of Takeda Pharmaceuticals where he established and led its global medical office.
XBiotech Names Head Clinical Operations
XBiotech, the developer of True Human therapeutic antibodies, has named Dawn McCollough VP of clinical operations. Ms. McCollough has more than two decades of global industry experience and has overseen all phases of clinical trial drug development across multiple therapeutic areas.
McCollough joins XBiotech from Biogen, where she served as head of medical research operations and led the medical research team, which included the company’s clinical trial review committee.
Dr. Martin Silverstein
Gilead Names Senior Leaders
Gilead Sciences has made two appointments to the company’s senior leadership team. Kevin Young as been appointed chief operating officer, and Martin Silverstein, M.D., has been appointed executive VP, strategy.
Mr. Young assumes responsibility for Gilead’s worldwide commercial organization, and facilities and operations. From 2004 through 2014, Mr. Young served as Gilead’s executive VP of commercial operations. Since 2014, he has held the role of senior advisor to the company.
Dr. Silverstein oversees Gilead’s corporate development, commercial planning and alliance management functions. He previously held the role of executive VP and chief strategy officer at Anthem from April 2014 through December 2015.
Dr. David Mantus
Dr. Rene Russo
Dr. Chris Stevens
Arsanis Makes Senior Appointments
Arsanis, a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, has promoted Rene Russo, Pharm.D., to president and CEO.
Since joining Arsanis as chief development officer in August 2015, Dr. Russo spearheaded the strategy for clinical studies for Arsanis’ lead program, ASN100, aimed at the prevention and treatment of serious Staphylococcus aureus infections. Before Arsanis, Dr. Russo served as VP, global medical affairs at Cubist Pharmaceuticals.
In addition to Dr. Russo’s appointment to CEO, David Mantus, Ph.D., has been appointed as chief development officer. In this role he drives strategy and planning for the continued clinical development of ASN100. Dr. Mantus joined Arsanis in 2015, bringing more than 20 years of experience in clinical development, regulatory affairs and quality assurance.
Arsanis has also recently recruited Ed Campanaro as senior VP, clinical operations to oversee Arsanis’ global clinical trials. Before joining Arsanis, Mr. Campanaro served as VP, clinical operations and data management for bluebird bio. Mr. Campanaro was also VP, clinical development operations at Cubist Pharmaceuticals.
The company has also appointed Anthony Christopher (Chris) Stevens, M.D., as chief medical officer.
In this role, Dr. Stevens drives the clinical development strategy for the full pipeline, including lead candidate ASN100 for the prevention and treatment of serious Staphylococcus aureus infections. Dr. Stevens joins Arsanis with more than 17 years of senior management and consulting experience in drug development.
Chase Pharmaceuticals Builds Senior Leadership Team
Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease, has expanded its senior management team with the appointment of Gary Charbonneau as senior VP, regulatory affairs and operations.
He joins Chase with more than 25 years of industry experience spanning regulatory, quality, and R&D operations. Most recently he was VP in charge of all international regulatory affairs for Allergan.
At Chase, Mr. Charbonneau is responsible for regulatory affairs and clinical and manufacturing operations where he participates in regulatory and development strategy as well as managing both clinical research organization and contract manufacturing relationships as the company executes its development program.
Epizyme Continues to Build Senior Leadership Team
Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Mr. Ros is responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat.
Mr. Ros comes to Epizyme from Sanofi, where he was most recently chief operating officer/global head of the oncology business unit.
Dr. Tarek Sahmoud
H3 Biomedicine Appoints Chief Medical Officer
H3 Biomedicine, a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, has appointed Tarek Sahmoud, M.D., Ph.D., as chief medical officer.
Dr. Sahmoud has more than 20 years of experience in oncology drug development and medical affairs. Before joining H3 Biomedicine, Dr. Sahmoud most recently served as VP, oncology clinical development and medical affairs for the U.S. business at Boehringer Ingelheim.
Cleave Biosciences Names Chief Business Officer
Cleave Biosciences, a biopharmaceutical company focused on the discovery and development of drugs that target protein homeostasis systems, has announced Tim Smith has joined the company as chief business officer. In this newly created executive position, Mr. Smith is responsible for business development, corporate development and investor relations as Cleave advances its novel protein homeostasis inhibitors currently under development for the treatment of cancer.
Mr. Smith has more than 15 years of experience in the life-sciences industry. Before joining Cleave, he was executive director, business development at Celgene.
Dr. Chris Storgard
Fate Therapeutics Appoints Chief Medical Officer
Fate Therapeutics, a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, has appointed Chris Storgard, M.D., chief medical dfficer. Dr. Storgard leads the design and execution of the company’s clinical trials for its programmed cellular immunotherapies.
Dr. Storgard has more than 20 years of experience in clinical drug development, most recently serving as an integral member of the executive team at Ardea Biosciences, a member of the AstraZeneca Group.
Arena Pharmaceuticals NAmes
President and CEO
Arena Pharmaceuticals has appointed Amit Munshi as president, CEO, and interim principal financial officer. Mr. Munshi also joins Arena’s board of directors.
Mr. Munshi brings to Arena more than 25 years of global biopharmaceutical industry experience in executive management, business development, product development, and portfolio management.
Most recently, Mr. Munshi served as president, CEO, and a director of Epirus Biopharmaceuticals, a publicly traded biopharmaceutical company.
Dr. Adrian Rabinowicz
Sancilio Pharmaceuticals Names Chief Medical Officer
Sancilio Pharmaceuticals has appointed Adrian Rabinowicz, M.D., as chief medical officer, responsible for SPCI’s clinical development, clinical strategy, and operational activities to advance the company’s pipeline.
Before joining Sancilio Pharmaceuticals, Dr. Rabinowicz spent more than 18 years in different global pharmaceutical and biotechnology companies, holding roles of increasing responsibility covering clinical development and medical affairs in a variety of therapeutic areas and was involved in numerous NDA submissions. Most recently, Dr. Rabinowicz was senior VP, clinical development and medical affairs at Acorda Therapeutics.
Aclaris Therapeutics Names Sales VP
Aclaris Therapeutics, a clinical-stage specialty pharmaceutical company, has appointed Kevin Scott, an experienced sales executive within the field of dermatology, as VP of sales.
Mr. Scott brings more than 20 years of pharmaceutical commercialization experience to Aclaris. He has substantial experience with specialty dermatology companies and has successfully led sales, sales training, operations, and managed markets teams.
Mr. Scott joins Aclaris from Novartis Pharmaceuticals, where he served as the northeast regional sales director.
Dr. Mark Chang
Veristat, a full-service clinical research organization (CRO), has strengthened its statistical consulting and adaptive design expertise with the appointment of Mark Chang, Ph.D., to the newly created position of senior VP of strategic statistical consulting. Dr. Chang helps clients evaluate and implement strategic, operational and technical efficiencies to advance products through the clinical trial and regulatory submission process.
Dr. Chang joins Veristat with more than 20 years of experience as a statistician at both biopharmaceutical firms and CROs, including AMAG Pharmaceuticals, Millennium/Takeda Pharmaceuticals, Parexel and MTRA.
Advanced Clinical Expands Clinical Operations Leadership
Advanced Clinical welcomes two new members to the clinical operations leadership team through the appointment of Cheryle Evans to senior VP, clinical and medical operations, and the addition of Sheri Madrid as executive director, clinical operations.
Ms. Evans brings wide-ranging experience to Advanced Clinical in leading clinical monitoring and project management teams. She has been instrumental in building and expanding clinical operations teams into new geographies as well as executing monitoring strategies worldwide.
Ms. Madrid’s therapeutic background is in epilepsy, infectious disease, gastrointestinal, respiratory, cardiovascular, neurovascular, hypertension, and diabetes. In her role, she oversees project management and clinical monitoring.
Patheon Appoints President
Patheon, a global provider of pharmaceutical development and manufacturing services, has appointed Michel Lagarde president. Mr. Lagarde joins Patheon from JLL Partners, a middle market private equity firm with a track record across several growing sectors, including healthcare, business/financial services, building products and aerospace/defense. He served as a member of Patheon’s board of directors since 2011.
Dr. Henning Steinhagen
Aptuit Names Executive VP, Drug Discovery and Development
Aptuit, which provides early discovery to mid-phase drug development services, has appointed Henning Steinhagen, Ph.D., as executive VP, drug discovery and development, and site-head Verona, completing Aptuit’s executive leadership team.
Dr. Steinhagen focuses on the growth of Aptuit as a leading partner research organization and provider of outsourced services in the early discovery and development space. He joins Aptuit from Grünenthal, a global pharmaceutical company, where he was senior VP, and head of global drug discovery.
PPD Appoints Veteran Immunochemistry Head
Pharmaceutical Product Development (PPD) has announced that Bruce Stouffer has joined PPD as executive director of immunochemistry in the PPD Laboratories’ bioanalytical lab.
Mr. Stouffer previously served as director of analytical and bioanalytical development for Bristol-Myers Squibb, where he managed a group of scientists with responsibilities including contract operations, quality control, and small and large molecule bioanalytical project management.
Dr. Louis Yu
AMRI Appoints Senior VP, Quality and Compliance
AMRI has hired Louis Yu, Ph.D., to fill the newly created position of senior VP of quality and compliance. Dr. Yu oversees all aspects of quality and cGMP compliance at all divisions of AMRI, including drug discovery services, API and drug product development and manufacturing.
Dr. Yu comes to AMRI with more than 30 years of leadership experience in the quality and R&D functions of branded and generic pharmaceutical companies. Most recently, he served as executive vice president, global quality and compliance for Perrigo, a manufacturer of private label and branded OTC and generic Rx pharmaceutical products.
BBK Worldwide Appoints President
BBK Worldwide, a leader in patient recruitment and engagement technologies and services, has appointed Matthew Kibby as president and chief innovation officer. Mr. Kibby has held a variety of senior positions in his 19-year tenure with the company and most recently led the company’s tech innovation and product development groups.
He steers the patient recruitment leader to achieve its vision of clinical research best practices that address patient needs and improve patient engagement. Mr. Kibby continues to report to BBK CEO and founding principal Joan Bachenheimer.
Dohmen Life Science Services
Dohmen has appointed Joe Nolan to president of Dohmen Life Science Services (DLSS). Mr. Nolan joins DLSS with more than 30 years of experience in the pharmaceutical industry, most recently serving as chief commercial officer and senior VP of Marathon Pharmaceuticals, a rare disease treatment company.
Mr. Nolan oversees Dohmen’s DLSS division, a one-stop-shop for drug and device companies to access capability ranging from compliance services, channel supply support, revenue cycle management and direct to patient care.
Dr. Paul Pfleiderer
Omnicom Health Group Appoints Leadership Team
Omnicom Health Group today announced the leadership team for TBWA\WorldHealth, the new agency created by the combination of two Omnicom healthcare specialist agencies, Corbett and LLNS.
Dan Chichester has been named chief digital officer. He was formerly the chief creative officer with LLNS.
His knowledge of interactive, emerging next-gen communications, including influencer networks, 3D printing, augmented reality and other progressive technologies, has allowed him to creatively engage with both consumers and healthcare professionals in innovative and effective ways.
Kristen Gengaro has been named managing partner.
Formerly a senior VP, director of client strategy and development with Corbett, she has spent her career working to advance science and the practice of healthcare.
She leads client relationships as well as have operational responsibility for project management, IT, events and office services.
Meaghan Onofrey has been named managing partner.
Formerly a senior VP with Omnicom Group, she is an experienced leader of integrated, cross-disciplinary teams, and will focus on leading client relationships, as well as taking on operational responsibilities for strategy, business development, PR and philanthropy.
Jamie Pfaff has been named chief creative officer. Formerly the executive creative director with Corbett, Mr. Pfaff has used his strategic skills and creative judgment to build brands for many of the world’s largest healthcare companies, helping clients earn record-breaking sales and top industry accolades.
Paul Pfleiderer, Ph.D., has been named chief strategy officer. Formerly a senior VP, director, market strategy and development with Corbett, Dr. Pfleiderer leads the agency’s efforts to bring disruption to healthcare, and create a best-in-class strategy team.
Klick Health Bolsters New York Office
Klick Health has opened a New York office and continues to add a wealth of seasoned agency talent to its team.
Leslie Doyle has been named VP, program director. She brings 20 years experience in project management, primarily for pharmaceutical and healthcare advertising agencies. Before joining Klick, she was VP group director of project management at Digitas Health Lifebrands
Yan Fossat has been named VP, Klick Labs. He joins the company from sister company Klick with deep expertise in access and reimbursement communications strategy and commercial activation.
Khawar Khokhar has been named executive VP, market Access & B2B. He joins Klick with deep expertise in access and reimbursement communications strategy and commercial activation.
Rachel McCready has been named creative strategist. A true health-marketing native, Ms. McCready has applied a “creategic” approach to more than 15 years of award-winning work covering nearly every specialty, organ system, and life stage. She has spent her career building brands in full-service, health-focused agencies, including her most recent role as executive VP, creative director at Havas Health.
Lance Paull has been named executive creative director. Formerly executive creative director at Evoke Health, Mr. Paull has spent the last 25 years at both independent and large global network agencies, including Ogilvy, Y&R, and Amarati.
Maureen Svoboda, has been named group account director, client services. She joins Klick with more than 20 years of pharmaceutical marketing experience, including 15+ years in brand leadership positions at Bristol-Myers Squibb and Johnson & Johnson, and the past four years at healthcare agencies.
Jennifer White has been named senior VP strategic partnerships. She has more than 15 years of consultative strategic business development experience spanning pharmaceuticals, medical devices, and consumer verticals in the Unites States.
Noriko Yokoi as senior VP, account planning. She brings more than 16 years of account planning experience to Klick. Previously, she held executive VP positions at AREA 23 and H4B Chelsea.
Digitas Health LifeBrands
Susan Manber has been promoted to chief planning officer, North America for Digitas Health LifeBrands, as well as Evolvr, and Publicis LifeBrands Medicus. In this newly created role, Ms. Manber explores and realizes a contemporary vision for planning and strategy in the health space.
MCS Healthcare Public Relations Appoints Senior VP
MCS Healthcare Public Relations has appointed Jennifer Silvent as senior VP. She rejoins MCS with more than a decade of healthcare PR experience. Her expertise spans a wide range of therapeutic categories with a successful track record of leading global multidisciplinary and multicultural teams.
Before returning to MCS, Ms. Silvent served as the global and U.S. product PR lead for several cardiovascular brands and pain compounds at one of the world’s largest pharmaceutical companies.
GSW Names Chief Creative Officer
Dave Sonderman is now chief creative officer of GSW, an industry leader in healthcare advertising and an inVentiv Health company. Previously he held the title of executive creative director. Mr. Sonderman focuses on agencywide initiatives that drive strategic creativity for GSW’s domestic and global healthcare clients.
Greater Than One Adds Global
The Greater Than One Group (GTO), an independent digital communications company, has named Kieran Walsh as global account director.
One responsibility that Mr. Walsh takes on immediately is overseeing GTO’s relationship with Grifols, a recent addition to the agency’s global client roster.
Mr. Walsh brings extensive pharmaceutical and direct to consumer advertising experience with Fortune 500 companies to GTO having held positions as managing director of Digitas Health, managing partner at JWT and partner, healthcare, at Rosetta.(PV)